Takeda Loses Appeal To Stop Mylan's Generic Gout Drug
Shooting down Takeda Pharmaceuticals' argument that a district court misinterpreted the terms of a licensing agreement, a split Federal Circuit panel on Friday upheld a lower court's decision declining to block...To view the full article, register now.
Already a subscriber? Click here to view full article